Maa: Euroopan unioni
Kieli: englanti
Lähde: EMA (European Medicines Agency)
onasemnogene abeparvovec
Novartis Europharm Limited
M09AX09
onasemnogene abeparvovec
Other drugs for disorders of the musculo-skeletal system
Muscular Atrophy, Spinal
Zolgensma is indicated for the treatment of:patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA Type 1, orpatients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene.
Revision: 13
Authorised
2020-05-18
38 B. PACKAGE LEAFLET 39 Package leaflet: Information for the user ZOLGENSMA 2 × 10 13 VECTOR GENOMES/ML SOLUTION FOR INFUSION onasemnogene abeparvovec This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects your child may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOUR CHILD IS GIVEN THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your child’s doctor or nurse. - If your child gets any side effects, talk to your child’s doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Zolgensma is and what it is used for 2. What you need to know before your child is given Zolgensma 3. How Zolgensma is given 4. Possible side effects 5. How to store Zolgensma 6. Contents of the pack and other information 1. WHAT ZOLGENSMA IS AND WHAT IT IS USED FOR WHAT ZOLGENSMA IS Zolgensma is a type of medicine called a ‘gene therapy’. It contains the active substance onasemnogene abeparvovec, which contains human genetic material. WHAT ZOLGENSMA IS USED FOR Zolgensma is used to treat spinal muscular atrophy (SMA), a rare, serious inherited disease. HOW ZOLGENSMA WORKS SMA occurs when there is a missing or abnormal version of a gene needed to make an essential protein called ‘Survival Motor Neuron’ (SMN) protein. Lack of SMN protein causes nerves that control muscles (motor neurons) to die. This results in muscles becoming weak and wasting away, with eventual loss of movement. This medicine works by supplying a fully functioning copy of the SMN gene which then helps the body produce enough SMN protein. The gene is delivered into the cells where it is needed using a modified virus that does not cause disease in humans. 40 2. WHAT YOU NEED TO KNOW BEFORE YOUR CHILD IS GIVEN ZOLGENSMA DO NOT US Lue koko asiakirja
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Zolgensma 2 × 10 13 vector genomes/mL solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 2.1 GENERAL DESCRIPTION Onasemnogene abeparvovec is a gene therapy medicinal product that expresses the human survival motor neuron (SMN) protein. It is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) based vector containing the cDNA of the human SMN gene under the control of the cytomegalovirus enhancer/chicken-β-actin-hybrid promoter. Onasemnogene abeparvovec is produced in human embryonic kidney cells by recombinant DNA technology. 2.2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL contains onasemnogene abeparvovec with a nominal concentration of 2 × 10 13 vector genomes (vg). Vials will contain an extractable volume of not less than either 5.5 mL or 8.3 mL. The total number of vials and combination of fill volumes in each finished pack will be customised to meet dosing requirements for individual patients depending on their weight (see sections 4.2 and 6.5). Excipient with known effect This medicinal product contains 0.2 mmol sodium per mL. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for infusion. A clear to slightly opaque, colourless to faint white solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Zolgensma is indicated for the treatment of: - patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the _SMN1_ gene and a clinical diagnosis of SMA Type 1, or - patients with 5q SMA with a bi-allelic mutation in the _SMN1_ gene and up to 3 copies of the _SMN2_ gene. 3 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment should be initiated and administered in clinical centres and supe Lue koko asiakirja